Shontae Howard
Family · Englewood, OHNPI 1255531315
Payments from drug & device makers
Across 144 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$462
- Vanda Pharmaceuticals Inc.$391
- AbbVie$334
- Lundbeck LLC$252
- Alkermes, Inc.$231
- Teva Pharmaceuticals USA, Inc.$208
- plus $1K from 15 others
What the payments were for
- Food & beverage$2,944100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $462 |
| Vanda Pharmaceuticals Inc. | 13 | $391 |
| AbbVie | 15 | $334 |
| Lundbeck LLC | 18 | $252 |
| Alkermes, Inc. | 11 | $231 |
| Teva Pharmaceuticals USA, Inc. | 13 | $208 |
| Indivior Inc. | 9 | $172 |
| Johnson & Johnson | 6 | $138 |
| E.r. Squibb & Sons, L.L.C. | 2 | $138 |
| USWM, LLC | 6 | $127 |
| Collegium Pharmaceutical, Inc. | 6 | $101 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Neurocrine Biosciences, Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Noven Therapeutics, LLC | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,944 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LucemyraLofexidine Hcl | 15 | $68,315 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $4,683 |
| Ondansetron OdtOndansetron | 14 | $290 |
| Gabapentin | 22 | $251 |
| Ibuprofen | 20 | $210 |
| Hydroxyzine Pamoate | 22 | $173 |
| Quetiapine Fumarate | 17 | $157 |
| Ropinirole Hcl | 18 | $155 |
| Promethazine Hcl | 18 | $142 |
| Trazodone Hcl | 26 | $117 |
| Cyclobenzaprine Hcl | 12 | $92 |
| Dicyclomine Hcl | 13 | $70 |
| Clonidine Hcl | 21 | $62 |
| IbuIbuprofen | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other family in Englewood
- Rhea JeffersEnglewood$27K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.